EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease

Stergios A Polyzos, Giovanni Targher

Current Obesity Reports · 08.03.2024 · 13 (2) · 242-255

DOI: 10.1007/s13679-024-00556-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Obesity Reports, online erschienen am 08.03.2024. Verfasst von Stergios A Polyzos und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece. spolyzos@auth.gr. Hauptthemen laut MEDLINE: Glucocorticoids, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Fatty Liver. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aristotle University of Thessaloniki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of the Review To summarize published data on the association between glucocorticoids and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on the possible pathophysiological links and related treatment considerations. Recent Findings Glucocorticoids, commonly used for managing many inflammatory and autoimmune diseases, may contribute to the development and progression of MASLD. Glucocorticoids may induce hyperglycemia and hyperinsulinemia, thus increasing systemic and hepatic insulin resistance, a hallmark of MASLD pathogenesis. Furthermore, glucocorticoids increase adipose tissue lipolysis, and hepatic de novo lipogenesis and decrease hepatic fatty acid β-oxidation, thus promoting MASLD development. Preclinical evidence also suggests that glucocorticoids may adversely affect hepatic inflammation and fibrosis. 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and 5α-reductase are implicated in the link between glucocorticoids and MASLD, the former enzyme increasing and the latter reducing the glucocorticoid action on the liver. Treatment considerations exist due to the pathogenic link between glucocorticoids and MASLD. Since iatrogenic hypercortisolism is common, glucocorticoids should be used at the minimum daily dose to control the subjective disease. Furthermore, the pharmacologic inhibition of 11β-HSD1 has provided favorable results in MASLD, both in preclinical studies and early MASH clinical trials. Summary Glucocorticoids are closely linked to MASLD pathophysiology, with specific clinical and therapeutic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucocorticoids11-beta-Hydroxysteroid Dehydrogenase Type 1Fatty LiverHumansInsulin ResistanceLiverAnimalsAdipose TissueNon-alcoholic Fatty Liver Disease

Stichwörter der Autor:innen

AdrenalsCortisolGlucocorticoidsMetabolic dysfunction-associated steatohepatitisMetabolic dysfunction-associated steatotic liver diseaseNonalcoholic fatty liver disease

Substanzen

Glucocorticoids11-beta-Hydroxysteroid Dehydrogenase Type 1

Autor:innen und Institutionen

  • First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece. spolyzos@auth.gr.
  • Department of Medicine, University of Verona, Verona, Italy.
  • Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (VR), Italy.

Förderung

  • Aristotle University of Thessaloniki

Zitieren

APA

Polyzos, S. A., & Targher, G. (2024). Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current Obesity Reports, 13(2), 242-255. https://doi.org/10.1007/s13679-024-00556-1

Vancouver

Polyzos SA, Targher G. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current Obesity Reports. 2024;13(2):242-255. doi:10.1007/s13679-024-00556-1

BibTeX
@article{Polyzos2024,
  author = {Polyzos, Stergios A and Targher, Giovanni},
  title = {Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Current Obesity Reports},
  year = {2024},
  volume = {13},
  number = {2},
  pages = {242--255},
  doi = {10.1007/s13679-024-00556-1}
}
Kostenlos starten →